Nasdaq

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT ...
Nasdaq

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III ...
Seeking Alpha

Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in ...

-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023 “We are pleased to present our findings on BCVA and CST from ...
Medscape

Intravitreal Injections and Endophthalmitis

Int Ophthalmol Clin. 2015;55(2):1-10. Surveys performed in 2009 indicated that >80% of retina specialists used topical antibiotics either before and/or after IVT injections. More recent surveys, ...
Morningstar

Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy ...

Dyno’s AI-designed capsids improved therapeutic gene delivery to eye, muscle and CNS compared to commonly used AAV capsids, showcasing improved delivery efficiency, target-organ specificity and ...